VOLUME 52 · SUBJECT INDEX

Acrodermatitis chronica atrophicans and Lyme arthritis, 402 ***P***
Age at menarche, HLA identity, RA, 322
AIDS, and hypertrophic osteoarthropathy: *correspondence*, 82
Alcohol, androgens, and RA: *correspondence*, 897
Algodystrophy, post-traumatic, effect of guanethidine on natural history: *concise report*, 467
Alkaline phosphatase isoenzyme activities in RA, 511
Alpha-1 acid glycoprotein, microheterogeneity, in rheumatoid arthritis, dependent on disease duration? 138
Amyloidosis AL, systemic, with temporal artery involvement, revealing lymphoplasmacytic malignancy, presenting as polymyalgia rheumatica: *concise report*, 158
Analgesics, peripheral, site of action: *leader*, 1
Androgens
  alcohol, and RA: *correspondence*, 897
  contraceptive pill, and RA: *hypothesis*, 470
  protective effect against inflammation induced cartilage degradation, male rodents, 285
Angiotensin converting enzyme, in RA: *correspondence*, 86
Ankylosing spinal hyperostosis, and coxopathy, with ossification of ligamentum teres: *concise report*, 306
Ankylosing spondylitis
  with cutaneous vasculitis and IgA glomerulonephritis: *concise report*, 61
  mortality and causes of death in 398 patients admitted to hospital, 174
  serum osteocalcin and vitamin D metabolites, 343
Anti-RA 33 antibodies, in juvenile chronic arthritis, 785
Anti-topoisomerase I antibody titres, rebound, after plasma exchange: *correspondence*, 246
Antibody humoral response analysis, contribution to nosological approach of Lyme borreliosis, 399 ***P***
Anticardiolipin antibodies, IgG, pathogenic serum, and idiotypic network, 742
Anticardiolipin antibody test, false negative results: *correspondence*, 167
Anticentromere antibodies in subjects with no apparent connective tissue disease, 586
Anticoagulant treatment, long term, for patients with antiphospholipid antibodies and venous thrombosis: *concise report*, 689
Antigen presenting cells, autologous, and bacterial antigens, responses of synovial fluid and peripheral blood mononuclear cells, 127
Antigens, oesophagus epithelium, defined by 'antikeratin antibodies', specific for RA, 749
Antikeratin antibodies
  in juvenile chronic arthritis, 785
  oesophagus epithelium antigens defined by, specific for RA, 749
Antineutrophil cytoplasmic antibody
  in polychondritis: *correspondence*, 384: *matters arising*, 895
  -positive vasculitis, in two sisters: *correspondence*, 385
Antinuclear antibodies
  in routine analysis, relevance of putative clinical associations, 110
  in scleroderma (systemic sclerosis) patients, and in blood relatives and spouses, 365
Antiperinuclear factor, in juvenile chronic arthritis, 785
Antiphospholipid antibodies
  absence in Behçet's disease: *correspondence*, 623
  and cutaneous manifestations, in suspected primary antiphospholipid syndrome, 219
  in pregnancy, and Buerger's disease: *correspondence*, 247: *matters arising*, 766
  and venous thrombosis, patients should receive long term anticoagulant treatment: *concise report*, 689
Antiphospholipid syndrome, and idiotypic network, 742
Antistreptolysin O, high titres associated with various rheumatic syndromes, 527
Aplastic anaemia, gold induced, unresponsive to G-CSF: *correspondence*, 488
Aristotle (384–322 BC): *rheumatological stamp*, 319
Arthritis
  and carcinoma: *correspondence*, 86
  in highland of Papua New Guinea, 49
  of the hip, and hip fractures, relation between, epidemiological study, 707
  in hyperimmunoglobulinaemia D: *correspondence*, 81: *matters arising*, 765
  menstrual, role of endometrium: *concise report*, 65: *correspondence*, 315
  unclassified, rational diagnosis and treatment, how clinical data may guide requests for Lyme serology and antibiotic treatment, 206
Arthrogenous inhibition, current issues: *review*, 829
Aspirin, and low dose methotrexate, in RA, renal effects: *concise report*, 613
Auranofin, in potentiation and inhibition of migration of human neutrophils, 595
Autoantibodies
  to centromere and histone, in scleroderma with severe pulmonary and vascular disease, 780
  to human leucocyte elastase, occurrence in Wegener's granulomatosis and other inflammatory disorders, 115
Autoimmune disease, oxidative DNA damage and cellular sensitivity to oxidative stress, 659
Autoimmune manifestations, multiple clinical and biological, in 50 workers after occupational exposure to silica, 534
Autoimmune MRL-lpr-lpr mice, IgG3 cryoglobulins in, immunopathogenesis, therapeutic approaches and relevance to similar human diseases, S48
Autoimmune rheumatic disease, immunogenetics, epidemiological approaches: *review*, 310
Autoimmunity, roles of bacterial and viral superantigens, S6
Azathioprine, for systemic connective tissue diseases, 6-thioguanine nucleotide accumulation in erythrocytes during treatment, monitoring possibility: *concise report*, 152

Bacterial antigens, and autologous antigen presenting cells, responses of synovial fluid and peripheral blood mononuclear cells, 127
Bacterial overgrowth, small intestinal, in RA, 503: *matters arising*, 895
Behçet's disease
  absence of antiphospholipid antibodies: *correspondence*, 623
  skin pathergy test with blunt and sharp needles compared: *concise report*, 823
Behçet's syndrome
  complete, affecting three sisters, HLA antigen familial study: *concise report*, 155
  effect of surgical cleaning of the skin on pathergy phenomenon: *concise report*, 619
Bone
  conservation, in radial diaphysis in RA, physical activity as determinant, 579
  cysts, in RA, gadolinium-DTPA enhanced MRI, 716
  formation in ankylosing spondylitis, 343
  formation and remodelling in RA, 338
Bone mineral density
  increased by adjuvant oestrogen treatment in postmenopausal RA: *concise report*, 302: *matters arising*, 835
  'normal', and dorsal vertebral fractures: *correspondence*, 244
  and osteoarthritis: *correspondence*, 316
  in recent onset RA, 21
Bone scintigraphy, prediction of OA progression, 557
Borrelia burgdorferi
  activation and killing by leucocytes in vitro, 409 ***P***
  B29 specific 27 kilodalton surface lipoprotein, molecular cloning of linear plasmid located gene encoding, 409 ***P***
  cellular immune reactions, 397 ***P***
  CSF, PCR based detection as predictor of treatment response in Lyme neuroborreliosis, 403 ***P***
  detected in blood, synovium, and skin of patients with Lyme arthritis, 409 ***P***
  differentiation of isolates from ticks and humans by different monoclonal antibodies in immunofluorescence, 410 ***P***
  DNA
    detection in clinical samples using nested PCR, 410 ***P***
    diagnostic detection by PCR, 401 ***P***
    investigations to detect in synovial fluid, 404 ***P***
  ecological factors in maintenance in wild animal populations, 405 ***P***
  environmental control, breaking the cycle, 406 ***P***
  enzootic cycle, Scotland, 388 ***P***
  genetic changes associated with attenuation, in vitro culture, 408 ***P***
  IgG antibodies in unclassified arthritis, 206
  infection
    mouse model, approach to understanding of pathogenesis and protection, 397 ***P***
    prolonged incidence of *I dammini* attachment to humans is associated with higher incidence, 405 ***P***
    serological follow up after treatment, 412 ***P***
    in urban park workers, potential new health hazard for inner city inhabitants, 387 ***P***
  interference of *E coli* antibodies with, 411 ***P***
  isolation from clinically normal skin six months after disappearance of erythema migrans, 410 ***P***
  isolation from normal CSF in seronegative erythema migrans and peripheral facial palsy, 411 ***P***
  multiple sequence alignment of osp operons of different isolates, 409 ***P***
  new polymorphic lipoprotein, molecular and immunological characterisation, 407 ***P***

non-cultivatable, typing by asymmetric PCR and sequencing, 410 *P*
PCR in direct detection from *I dammini*, 406 *P*
PCR and ticks, comparison of vertebrate hosts and habitat or vegetation as sources, 406 *P*
plasmid analysis, Chinese isolates, 410 *P*
protective activity of antisera against isolates, from various geographical origins, 409 *P*
sectional uptake and cytosolic processing by human phagocytes, 409 *P*
sensu lato
chromosomes, physical and genetic maps, 397 *P*
repeated DNA sequences on circular and linear plasmids, 410 *P*
serological responses, British dogs, 405 *P*
shown by PCR from skin biopsy specimen after fly bite, 407 *P*
within islands in Gulf of Maine, OspB sequence variation, 408 *P*
Borrelia spp., associated with Lyme borreliosis, PCR, 408 *P*
chemotaxonomy, 408 *P*
Brainstem and spinal cord, in end stage rheumatoid arthritis, neuropathology, implications for treatment, 629
Bronchiectasis and RA, clinical study, 776
Brown's syndrome, acquired, in SLE: *concise report*, 63; *correspondence*, 385: *matters arising*, 835
Buerger's disease ar[illegible] antiphospholipid antibodies in pregnancy: *correspondence*, 247: *matters arising*, 766
Bupivacaine, modified suprascapular nerve block, in shoulder pain control, RA, 215

C1q for nephritis in SLE, predictive value of IgG autoantibodies against, 851
Calcinosis, pericardial but not peripheral, and CREST syndrome: *correspondence*, 767
Calcium pyrophosphate dihydrate crystals, opsonized, enhanced crystal induced neutrophil responses by, 599
Calderdale Rheumatic Disablement Survey, impact of disablement due to rheumatic disorders, 6
Campylobacter serology, Lyme borreliosis patients give false positive reactivity, cross reaction or result of polyclonal stimulation? 411 *P*
Carbon monoxide transfer factor and static lung compliance compared, in early pulmonary disease in systemic sclerosis, 725
Carcinoma, and arthritis: *correspondence*, 86
Cartilage collagen gene, multiallelic polymorphism, no association with osteoarthrosis: *concise report*, 762
Cartilage degradation
by polymorphonuclear leucocytes, in vitro assessment of pathogenic mechanisms, 27
inflammation induced, protective effect of androgens, male rodents, 285
inhibition by U27391, 37
Cartilage destruction, blocking with metalloproteinase inhibitors, valid therapeutic target? *leader*, 769
Cartilage integrity in vitro, effect of tenidap, 292
CD69 antigen expression on synovial fluid T cells in RA and other chronic synovitis, 457
CD8+ cells, variation with treatment in PMR/GCA, 730
Cell adhesion molecules, distribution in skeletal muscle in SLE, 667
Centromere, autoantibodies to, in scleroderma with severe pulmonary and vascular disease, 780
Cheiroarthropathy, diabetic, compartment syndrome, and stiff joints: *correspondence*, 840
Chingford study, cigarette smoking and osteoarthritis risk, women, 93
Chondrocalcinosis, articular, prevalence in elderly subjects, rural area of Catalonia, 418
Chondrocytes
hydrostatically loaded articular cartilage, altered Golgi apparatus, 192
isolated bovine articular, type II TGF-β receptor, correlation with TGF-β responses, 812
Chronic fatigue syndrome and fibromyalgia induced by Lyme disease, 404 *P*
Colchicine, therapeutic value in psoriatic arthritis: *concise report*, 826
Collagen
spiralled, dysplastic and intracellular, and Luse bodies in rheumatoid connective tissues, 278
type I, increased degradation correlates with disease severity in RA, 866
Compartment syndrome, stiff joints, and diabetic cheiroarthropathy: *correspondence*, 840
Complement activating properties of monoreactive and polyreactive IgM rheumatoid factors, 795
Contraceptive pill, RA, and androgens: *hypothesis*, 470
Coping with RA: *leader*, 553
Corrections, 88, 624
Corticosteroids, as risk factors in RA with severe peptic ulceration, 771
Coxopathy associated with ankylosing spinal hyperostosis, with ossification of ligamentum teres: *concise report*, 306
CREST syndrome
and large vessel occlusive disease: *concise report*, 464: *matters arising*, 837
with pericardial but not peripheral calcinosis: *correspondence*, 767
Crystal induced neutrophil, enhanced responses by opsonisation of CPPD crystals, 599
CS1 adhesion motif of fibronectin, role in T cell adhesion to synovial membrane and peripheral lymph node endothelium, 672
Cutaneous manifestations associated with antiphospholipid antibodies in suspected primary antiphospholipid syndrome, 219
Cyclosporin, in idiopathic orbital myositis: *correspondence*, 84
Cyclosporin A, in eosinophilia myalgia syndrome: *correspondence*, 81
Cytokine expression in synovial membranes in RA and osteoarthritis, 870

Danazol in menstrual arthritis: *concise report*, 65
Degenerative arthritis, synovial localisation of vitronectin receptor immunoreactivity and tartrate resistant acid phosphatase activity, 133
Dehydroepiandrosterone, depressed levels in postmenopausal women with RA, and axial bone density, 211
Dementia, in Lyme disease, 404 *P*
Dermatomyositis
no persistence of enterovirus or encephalomyocarditis virus RNA in muscle, 575
/polymyositis, adult onset, clinical and laboratory features and treatment response, 75 patients, 857
Diabetic cheiroarthropathy, compartment syndrome, and stiff joints: *correspondence*, 840
Diclofenac/misoprostol
osteoarthritis and NSAID ulcer disease: *leader*, 841
piroxicam, and naproxen, in osteoarthritis, efficacy and gastroduodenal safety, 881
Dilated cardiomyopathy, no serological evidence of infection with *B burgdorferi*, 403 *P*
Dioscorides, Pedanius, ca AD 40 to 90: *rheumatological stamp*, 492
Disability, and GALS locomotor screen, 886
Disability scores, functional, self report, and use of devices, in RA, 497
Disablement, due to rheumatic disorders, impact, Calderdale Rheumatic Disablement Survey, 6
Disseminated gonococcal infection, in elderly patient: *correspondence*, 83
DNA antibody, and lupus nephritis, 14
Dorsal vertebral fractures with 'normal' bone mineral density: *correspondence*, 244
Drug abusers, osteoarticular infection, and HIV, 570

End stage rheumatoid arthritis, neuropathology of brainstem and spinal cord, implications for treatment, 629
Endothelium damage and von Willebrand factor antigen: *correspondence*, 86
***Enterobacter cloacae* vertebral infection**, in heroin addict with HIV infection: *matters arising*, 695
Eosinophilia myalgia syndrome, use of cyclosporin A: *correspondence*, 81
Epstein-Barr virus carrying cells, absence in synovial membranes and subcutaneous nodules of RA: *concise report*, 608
Erythema induratum, and pulmonary tuberculosis: *correspondence*, 766
Erythema migrans
isolation of *B burgdorferi* from clinically normal skin six months after disappearance of, 410 *P*
isolation of *B burgdorferi* from normal CSF in seronegative patients, 411 *P*
western blotting improves detection of specific IgM in serum of, 410 *P*
Escherichia coli antibodies, interference with *B burgdorferi*, 411 *P*
Exercise, von Willebrand factor, and ischaemia/reperfusion injury: *correspondence*, 245

Facial palsy, peripheral, isolation of *B burgdorferi* from normal CSF in seronegative patients, 411 *P*
Femoral head articular cartilage, adaptation to long distance running exercise, young beagles, 369
Femoral head osteonecrosis in primary hypertrophic osteoarthropathy: *correspondence*, 386
Fibrinolysis, baseline plasma, and its correlation with clinical manifestations in Raynaud's phenomenon, 443
Fibromyalgia
and chronic fatigue syndrome, induced by Lyme disease, 404 *P*
elusive 'α-δ' sleep: *correspondence*, 245
and joint hypermobility in schoolchildren, 494
in the workplace, a 'management' problem: *leader*, 249: *matters arising*, 836
Fibronectin, CS1 adhesion motif, role in T cell adhesion to synovial membrane and peripheral lymph node endothelium, 672
Foam cells containing oxidised LDL, presence in synovial membrane, RA: *concise report*, 677
Folate supplementation and methotrexate: *correspondence*, 315
Food intolerance in RA: *correspondence*, 88
Fractures, dorsal vertebral, with 'normal' bone mineral density: *correspondence*, 244

Gadolinium-DTPA enhanced MRI of bone cysts in RA, **716**
Gait, Arms, Legs, Spine (GALS) locomotor screen and disability, **886**
Galen (130–203 AD): *rheumatological stamp*, **172**
GALS locomotor screen and disability, **886**
Gastrointestinal events, risk factors for, in RA, **771**
Giant cell arteritis
plasma viscosity as predictor of disease activity, **104**
/polymyalgia rheumatica, after two months of treatment, clinical and laboratory course, **847**
and polymyalgia rheumatica, variation in CD8+ cells with treatment, **730**
and subacute thyroiditis, simultaneous onset: *correspondence*, **839**
Giant cells in arthritic synovium, **182**
Glycosaminoglycan
production by scleroderma fibroblasts in culture, effects of methotrexate, **758**
synthesis, inhibition by muramyl dipeptide and lipopolysaccharide, **32**
Glycosylation, protein, role in immune regulation, **S22**
Gold induced aplastic anaemia, unresponsive to G-CSF: *correspondence*, **488**
Gold induced nephropathy in RA, and HLA class II genes: *concise report*, **300**
Gold treatment, as gastric antibacterial and NSAID protective: *leader*, **89**; *matters arising*, **623**
Golgi apparatus, altered, in hydrostatically loaded articular cartilage chondrocytes, **192**
Gonococcal infection, disseminated, in elderly patient: *correspondence*, **83**
Gout, towards a coherent terminology: now and then, **693**
Guanethidine, effect on natural history of post-traumatic algodystrophy: *concise report*, **467**

Haemolytic streptococci, beta
and musculoskeletal sepsis in adults: *review*, **483**
and reactive arthritis in adults: *review*, **475**
Haemophilic haemarthrosis, radiosynovectomy with yttrium-90 silicate, long term follow up: *concise report*, **548**
Haemophilus aphrophilus, causing spondylodiscitis, vacuum sign: *correspondence*, **84**
Heat shock protein, differential overexpression and clinical relevance in SLE, **436**
Heroin addict with HIV infection, *E. cloacae* vertebral infection: *matters arising*, **695**
Hip fractures, and arthritis of the hip, relation between, epidemiological study, **707**
Hip, osteoarthritis, hospital referred, radiographic progression, **263**
Hippocrates: *rheumatological stamp*, **4**
Histone, autoantibodies to, in scleroderma with severe pulmonary and vascular disease, **780**
HIV infection
in heroin addict, *E. cloacae* vertebral infection: *matters arising*, **695**
and osteoarticular infection in drug abusers, **570**
HLA
antigen, familial study in complete Behçet's syndrome affecting three sisters: *concise report*, **155**
class II genes, and gold induced nephropathy in RA: *concise report*, 300
identity, and age at menarche, RA, **322**
linkage with RA, **638**
HLA-DR4, examination as severity marker for RA, Greek patients, **517**
HLA-DR, RA sex ratios, and testosterone: *correspondence*, **244**
HLA-DRB1*04, and RA, in newly diagnosed cases from the community, absence of association between: *concise report*, **539**
HLA-DRβ and DQβ polymorphism, in Chinese with RA, molecular analysis: *concise report*, **610**
Hormone replacement therapy
effect on markers of bone metabolism in RA, **302**: *matters arising*, **835**
and osteoporosis prevention: *hypothesis*, **74**
hsp65, mycobacterial, increased antibodies, lack of association to RA: *concise report*, **542**
HTLV-I positive RA, synovial fluid T cells: *correspondence*, **166**
Human leucocyte elastase, occurrence of autoantibodies to, in Wegener's granulomatosis and other inflammatory disorders, **115**
Hyaluronic acid, molecular weight, effects and action mechanisms on experimental joint pain, rats, **817**
Hydrostatically loaded articular cartilage chondrocytes, altered Golgi apparatus, **192**
Hydroxychloroquine
for primary Sjögren's syndrome, **360**
and sulphasalazine, alone and in combination, in RA, **711**
Hyperimmunoglobulinaemia D, and arthritis: *correspondence*, **81**: *matters arising*, **765**
Hyperimmunoreactivity, cellular, to rubella virus synthetic peptides, in chronic rubella associated arthritis, **590**
Hyperlipidaemia, musculoskeletal manifestations, **44**
Hypertrophic osteoarthropathy and AIDS: *correspondence*, **82**

Immune regulation, role of protein glycosylation, **S22**
Immunisation, can it trigger RA: *leader*, **843**
Immunogenetics of autoimmune rheumatic disease, epidemiological approaches: *review*, **310**
Immunoglobulin A glomerulonephritis, and cutaneous vasculitis, in ankylosing spondylitis: *concise report*, **61**
Immunoglobulin G
anticardiolipin antibodies, pathogenic serum, and idiotypic network, **742**
autoantibodies, predictive value against C1q for nephritis in SLE, **851**
Immunoglobulin G3 cryoglobulins in autoimmune MRL-lpr-lpr mice, immunopathogenesis, therapeutic approaches and relevance to similar human diseases, **S48**
Immunoglobulin M rheumatoid factors, monoreactive and polyreactive, complement activating properties, **795**
Immunology of the rheumatic diseases, **S1–S54**
Immunosuppressive treatment, in stroke and renal failure: *correspondence*, **165**
Immunotherapy, causing rheumatic disease: *correspondence*, **165**
Inclusion body myositis, underdiagnosed condition? **147**
Inflammation induced cartilage degradation, protective effect of androgens, male rodents, **285**
Inflammatory arthritis
and possible clearance of PMNLs from synovial fluid by cytophagocytic mononuclear cells, **121**
synovial localisation of vitronectin receptor immunoreactivity and tartrate resistant acid phosphatase activity, **133**
Insufficiency fractures of the sacrum: *correspondence*, **621**
Insulin-like growth factor I, and steroids, maintain proteoglycan synthesis, **734**
Insulin related growth factor 1, levels in osteoarthritis of the knee: *concise report*, **229**
Integrins, α4 and β1, and VCAM-1, in lymphocyte aggregates in Sjögren's syndrome and RA, **806**
Interleukin 1 induced destruction of articular cartilage, protection by TGF-β, **185**
Interleukin 1-beta induced cartilage degradation in vitro, inhibition by metalloproteinase inhibitor U27391, **37**
Interleukin-2 receptor
levels in RA, clinical and laboratory parameters affecting, **876**
serum concentrations, RA, effect of second line drugs: *concise report*, **58**
Interleukin 6, serum levels in RA: *concise report*, **232**
Intervertebral discs, pressure-volume curves, multipoint determination, **142**
Ion trapping, and NSAID efficacy: *hypothesis*, **241**
Ipsilateral hemiparesis, rapid development of tophus following: *concise report*, **308**
Iron, in joint inflammation: *review*, **67**
Ischaemia/reperfusion injury, von Willebrand factor, and exercise: *correspondence*, **245**
Ixodes dammini, prolonged attachment to humans is associated with higher incidence of *B burgdorferi* infection, **405** ***P***

Jewish Israeli groups, SLE, **268**
Joint destruction, molecular and cellular mechanism, in RA, two cellular mechanisms explain joint destruction? **S39**
Joint hypermobility and fibromyalgia in schoolchildren, **494**
Joint inflammation, and iron: *review*, **67**
Joint pain
chronic, and sympathetic nervous system: *matters arising*, **552**
effects of molecular weight of hyaluronic acid and its action mechanisms, rat, **817**
Joint space narrowing, OA progression, prediction by bone scintigraphy, **557**
Juvenile chronic arthritis, occurrence of antiperinuclear, antikeratin, and anti-RA 33 antibodies, **785**

Knee, osteoarthritis
definition for epidemiological studies, **790**
determinants of disability, **258**
insulin related growth factor 1 levels: *concise report*, **229**
radiographic patterns and associations in patients referred to hospital, **520**

Labial capillary microscopy, in systemic sclerosis, **564**
Large vessel occlusive disease, associated with CREST syndrome and scleroderma: *concise report*, **464**: *matters arising*, **837**
Laser treatment, low power, in RA, double blind randomised trial, **703**
Lepromatous leprosy, borderline, and chronic lymphocytic leukaemia, and benign rheumatoid nodules: *concise report*, **685**
Leukaemia, chronic lymphocytic, and borderline lepromatous leprosy, and benign rheumatoid nodules: *concise report*, **685**
Ligamentum teres, ossification, and coxopathy associated with ankylosing spinal hyperostosis: *concise report*, **306**
Lipopolysaccharide and muramyl dipeptide inhibition of glycosaminoglycan synthesis, **32**

Lipoprotein, oxidised low density, presence of foam cells containing, in synovial membrane, RA: *concise report*, **677**
Low back pain
simple, rest or active exercise? *leader*, **317**
understanding paraspinal muscle dysfunction, a way forward? *leader*, **413**
Low power laser treatment in RA, double blind randomised trial, **703**
Lupus, assessment, where are we now? *leader*, **169**
Lupus nephritis, significance of ELISA for DNA antibody, **14**
Luse bodies, and spiralled, dysplastic and intracellular collagen, in rheumatoid connective tissues, **278**
Lyme arthritis
and acrodermatitis chronica atrophicans, **402** ***P***
B burgdorferi located in blood, synovium, and skin, **409** ***P***
expression of public idiotypes, **199**
pathogenesis, diagnosis, and treatment, **391** ***P***
the Somerset experience, **402** ***P***
Lyme borreliosis
Australia, **407** ***P***
and *Borrelia* spp., PCR, **408** ***P***
in children, **390** ***P***
clinical manifestations, **403** ***P***
clinical and serological study, **403** ***P***
contribution of antibody humoral response analysis to nosological approach, **399** ***P***
detection, comparative evaluation of commercially available diagnostic tests, **411** ***P***
ecology, Sweden, **396** ***P***
enzootic cycle for *B burgdorferi*, Scotland, **388** ***P***
geographic diversity, **396** ***P***
laboratory diagnosis, pitfalls, **387** ***P***
ocular manifestations, **402** ***P***
paediatric, reinfection: *correspondence*, **695**
patients give false positive reactivity in campylobacter serology, cross reaction or result of polyclonal stimulation? **411** ***P***
protective immunity, **400** ***P***
serology, comparative study of cross reactivity, **411** ***P***
therapeutic options, **393** ***P***
and tick-borne encephalitis, seroconversion, Dutch military personnel, **406** ***P***
UK, **387** ***P***
ecology, **394** ***P***
Lyme carditis
aspects, **389** ***P***
clinical update, **402** ***P***
Lyme disease
in British horses, **405** ***P***
and dementia, **404** ***P***
ecology, role of host abundance, **405** ***P***
epidemiology, Italy, **407** ***P***
equine case, **407** ***P***
experimental cat model, **408** ***P***
experimental mouse model, **408** ***P***
inducing fibromyalgia and chronic fatigue syndrome, **404** ***P***
in Scotland, results of serological study in sheep, **406** ***P***
serodiagnosis, UK, **400** ***P***
test kits, comparative evaluation, **412** ***P***
Lyme neuroborreliosis
chronic versus subacute manifestations, MRI, **402** ***P***
clinical manifestations and treatment, **389** ***P***
PCR based detection of CSF *B burgdorferi* as predictor of treatment response, **403** ***P***
Lyme serology in unclassified arthritis, **206**
Lyme and tick-borne encephalitis (TBE), seroepidemiological study, **404** ***P***
Lymphocytes, synovial, and aetiology of synovitis, **S17**: *matters arising*, **765**
Lymphocytic lymphoma, and rapidly progressive sacroiliitis: *concise report*, **239**
Lymphoplasmacytic malignancy, presenting as polymyalgia rheumatica, systemic amyloidosis AL with temporal artery involvement revealing: *concise report*, **158**

Magnetic resonance imaging, gadolinium-DTPA enhanced, of bone cysts in RA, **716**
Menstrual arthritis, role of endometrium: *concise report*, **65**: *correspondence*, **315**
Metalloproteinase inhibitors
blocking cartilage destruction, valid therapeutic target? *leader*, **769**
in synovial fluid, identification, **177**
U27391, in inhibition of interleukin 1-beta induced cartilage degradation in vitro, **37**
Methotrexate
effects on glycosaminoglycan production by scleroderma fibroblasts in culture, **758**
and folate supplementation: *correspondence*, **315**
low dose, and aspirin, in RA, renal effects: *concise report*, **613**
Methotrexate osteopathy in rheumatic disease, **582**
Microfibrillar elements in synovial joint, presence of type VI collagen and fibrillin-containing microfibrils, **449**
Microglobulin, β2, measurements in saliva of patients with primary Sjögren's syndrome, influence of flow: *concise report*, **461**
Misoprostol/diclofenac
osteoarthritis and NSAID ulcer disease: *leader*, **841**
piroxicam, and naproxen, in osteoarthritis, efficacy and gastroduodenal safety, **881**
Multiallelic polymorphism of cartilage collagen gene, no association with osteoarthrosis: *concise report*, **762**
Muramyl dipeptide and lipopolysaccharide inhibition of glycosaminoglycan synthesis, **32**
Musculoskeletal manifestations in hyperlipidaemia, **44**
Musculoskeletal pain syndromes, paediatric, understanding, recent developments: *leader*, **490**
Musculoskeletal sepsis, in adults, and β haemolytic streptococci: review, **483**
Myocardial antimyosin scintigraphy, in diagnosis of myocardial disease in polymyositis: *concise report*, **235**
Myocardial disease, in polymyositis, myocardial antimyosin scintigraphy in diagnosis: *concise report*, **235**
Myositis, inclusion body, underdiagnosed condition?, **147**

Naproxen, piroxicam, and diclofenac/misoprostol, in osteoarthritis, efficacy and gastroduodenal safety, **881**
Neopterin, urine, as parameter of disease activity in SLE, **429**
Nephritis, in SLE, environmental factors predicting, **720**
Nerve block, modified suprascapular, with bupivacaine, in shoulder pain control, RA, **215**
Neuropathology of the brainstem and spinal cord, in end stage rheumatoid arthritis, implications for treatment, **629**
Neutrophil(s)
activation by synovial fluid in RA, **347**
crystal induced, enhanced responses by opsonisation of CPPD crystals, **599**
potentiation and inhibition of migration by auranofin, **595**
synovial fluid, receptor expression, in RA, **354**
Nodules, rheumatoid
benign, in woman with chronic lymphocytic leukaemia and borderline lepromatous leprosy: *concise report*, **685**
differential diagnosis and immunohistological findings: *leader*, **625**
Non-Hodgkin's lymphoma, initial manifestation: *correspondence*, **85**
Non-steroidal anti-inflammatory drugs
as risk factors for serious gastrointestinal events in RA, **771**
so variable in their efficacy, why, description of ion trapping: *hypothesis*, **241**
ulcer disease, and osteoarthritis: *leader*, **841**
Notes and news, **5, 91, 173, 252, 320, 416, 493, 555, 627, 699, 845**
Nottingham Office, one year on: *leader*, **489**

Ocular manifestations of Lyme borreliosis, **402** ***P***
Oesophagus, epithelium antigens defined by 'antikeratin antibodies', specific for RA, **749**
Oestrogen
adjuvant therapy, no improved disease activity in postmenopausal patients with RA, **862**
adjuvant treatment increases bone mineral density in postmenopausal women with RA: *concise report*, **302**: *matters arising*, **835**
replacement, for osteoporosis prevention should no longer be a bone of contention: *hypothesis*, **74**
Orbital myositis, idiopathic, treatment with cyclosporin: *correspondence*, **84**
Osteoarthritis
cytokine expression in synovial membranes, **870**
diclofenac/misoprostol, piroxicam, and naproxen, efficacy and gastroduodenal safety, **881**
elusive 'α-δ' sleep: *correspondence*, **245**
and NSAID ulcer disease, diclofenac/misoprostol: *leader*, **841**
patellofemoral, radiographic assessment, **655**
radiographic changes, association with symptoms and synovial fluid particles, 300 knees, **97**
risk, and cigarette smoking, women, Chingford study, **93**
Osteoarthritis of the hip, hospital referred, radiographic progression, **263**
Osteoarthritis of the knee
definition for epidemiological studies, **790**
determinants of disability, **258**
insulin related growth factor 1 levels: *concise report*, **229**
progression, prediction by bone scintigraphy, **557**
radiographic patterns and associations in patients referred to hospital, **520**
Osteoarthropathy, primary hypertrophic, and femoral head osteonecrosis: *correspondence*, **386**

Osteoarthrosis, not associated with multiallelic polymorphism of cartilage collagen gene: *concise report*, **762**
Osteoarticular infection, and HIV, in drug abusers, **570**
Osteocalcin, serum
and carboxyterminal propeptide of type I procollagen, RA, **338**
and vitamin D metabolites, in ankylosing spondylitis, **343**
Osteoporosis, oestrogen replacement for prevention: *hypothesis*, **74**

Paget's disease of bone
treated with five day course of oral tiludronate, **54**
treatment with single dose intravenous pamidronate: *concise report*, **616**
Palisading cells of rheumatoid nodules, comparison with synovial intimal cells, **801**
Pamidronate, single dose, intravenous, in Paget's disease of bone: *concise report*, **616**
Papua New Guinea, highlands, arthritis, **49**
Paraspinal muscle dysfunction, in low back pain, understanding, a way forward? *leader*, **413**
Park workers, *B burgdorferi* infection, potential new health hazard for inner city inhabitants, **387** ***P***
Patellofemoral osteoarthritis, radiographic assessment, **655**
Percutaneous transluminal coronary angioplasty, polyarteritis nodosa following: *correspondence*, **247**: *matters arising*, **897**
Peripheral analgesics, site of action: *leader*, **1**
Peripheral blood mononuclear cells and synovial fluid, responses to bacterial antigens and autologous antigen presenting cells, **127**
Physical activity as determinant of bone conservation in radial diaphysis in RA, **579**
Physical treatments, new, evaluating: *leader*, **697**
Piroxicam, diclofenac/misoprostol, and naproxen, in osteoarthritis, efficacy and gastroduodenal safety, **881**
Plasma exchange, rebound of anti-topoisomerase I antibody titres after: *correspondence*, **246**
Plasma fibrinolysis in RA, and impaired endothelial fibrinolytic response in those complicated by vasculitis, **643**
Plasma transfusion, autologous pregnancy, in RA: *correspondence*, **316**
Plasma viscosity, in giant cell arteritis, as predictor of disease activity, **104**
Polyarteritis nodosa, following angioplasty: *correspondence*, **247**: *matters arising*, **897**
Polychondritis, antineutrophil cytoplasmic antibodies: *correspondence*, **384**: *matters arising*, **895**
Polymerase chain reaction, in direct detection of *B burgdorferi* from *I dammini*, **406** ***P***
Polymorphonuclear leucocytes
and cartilage degradation, in vitro assessment of pathogenic mechanisms, **27**
possible clearance from synovial fluid by cytophagocytic mononuclear cells, and inflammatory arthritis, **121**
Polymyalgia rheumatica
/giant cell arteritis, after two months of treatment, clinical and laboratory course, **847**
and giant cell arteritis, variation in CD8+ cells with treatment, **730**
presentation in systemic amyloidosis AL with temporal artery involvement revealing lymphoplasmacytic malignancy: *concise report*, **158**
Polymyositis
/dermatomyositis, adult onset, clinical and laboratory features and treatment response, 75 patients, **857**
myocardial disease, myocardial antimyosin scintigraphy in diagnosis: *concise report*, **235**
no persistence of enterovirus or encephalomyocarditis virus RNA in muscle, **575**
Postmenopause
with RA, adjuvant oestrogen therapy does not improve disease activity, **862**
and RA, adjuvant oestrogen treatment and bone mineral density: *concise report*, **302**: *matters arising*, **835**
Postural variation in von Willebrand factor antigen: *correspondence*, **82**
Pressure-volume curves, in human intervertebral discs, multipoint determination, **142**
Protein glycosylation, role in immune regulation, **S22**
Proteoglycan synthesis, steroids and insulin-like growth factor I maintain, **734**
Psoriatic arthritis, therapeutic value of colchicine: *concise report*, **826**
Pubic rami, stress fractures, in RA: *concise report*, **681**
Public idiotypes, expression in Lyme arthritis, **199**
Pulmonary disease, early, in systemic sclerosis, carbon monoxide transfer factor and static lung compliance compared, **725**
Pulmonary tuberculosis, and erythema induratum: *correspondence*, **766**

Radial diaphysis, in RA, physical activity as determinant of bone conservation, **579**
Radiographic assessment of patellofemoral osteoarthritis, **655**
Radiological progression in RA
genetic markers, **327**
how many patients are required in a treatment trial to test disease modification, **332**
Radiosynovectomy with yttrium-90 silicate in haemophilic haemarthrosis, long term follow up: *concise report*, **548**
Raynaud's phenomenon, and baseline plasma fibrinolysis, **443**
Reactive arthritis, adult, and β haemolytic streptococci: *review*, **475**
Refrigeration preserves synovial fluid cytology: *correspondence*, **384**
Renal effects of aspirin and low dose methotrexate in RA: *concise report*, **613**
Renal failure, and stroke, immunosuppressive treatment: *correspondence*, **165**
Repetitive strain injury: *leader*, **249**: *matters arising*, **836**
Retroviral proteins, in Sjögren's syndrome, antibodies to: *correspondence*, **621**
Rhazes (AD 850-932): *rheumatological stamp*, **698**
Rheumatic disease
following immunotherapy: *correspondence*, **165**
immunology, **S1-S54**
Rheumatic fever, and high titres of antistreptolysin O, **527**
Rheumatic syndromes, associated with high titres of antistreptolysin O, differential diagnosis with rheumatic fever, **527**
Rheumatoid arthritis
absence of Epstein-Barr virus: *concise report*, **608**
alcohol, and androgens: *correspondence*, **897**
alkaline phosphatase isoenzyme activities, **511**
and angiotensin converting enzyme: *correspondence*, **86**
antiquity: *correspondence*, **316**
and bronchiectasis, clinical study, **776**
can it be triggered by immunisation: *leader*, **843**
components of health, quality of life questionnaires and clinical and laboratory variables, **650**
contraceptive pill, and androgens: *hypothesis*, **470**
coping: *leader*, **553**
cytokine expression in synovial membranes, **870**
detection of Luse bodies, spiralled, dysplastic and intracellular collagen, **278**
end stage, neuropathology of brainstem and spinal cord, implications for treatment, **629**
examination of HLA-DR4 as severity marker, Greek patients, **517**
expression of CD69 antigen on synovial fluid T cells, **457**
extra-articular manifestations, risk factors for serious gastrointestinal events, **771**
and food intolerance: *correspondence*, **88**
gadolinium-DTPA enhanced MRI of bone cysts, **716**
gold induced nephropathy, and HLA class II genes: *concise report*, **300**
and HLA-DRB1*04, in newly diagnosed cases from the community, absence of association between: *concise report*, **539**
HLA identity, and age at menarche, **322**
hydroxychloroquine and sulphasalazine alone and in combination, **711**
IL-2 receptor levels, clinical and laboratory parameters affecting, **876**
increased type I collagen degradation correlates with disease severity, **866**
joint destruction, molecular and cellular mechanisms, two cellular mechanisms explain joint destruction? **S39**
lack of association of increased antibody levels to mycobacterial hsp65: *concise report*, **542**
linkage with HLA, **638**
low power laser treatment, double blind randomised trial, **703**
microheterogeneity of alpha-1 acid glycoprotein dependent on disease duration?, **138**
molecular analysis of HLA-DRβ and DQβ polymorphism, Chinese: *concise report*, **610**
neutrophil activation by synovial fluid, **347**
oesophagus epithelium antigens defined by 'antikeratin antibodies' specific for, **749**
physical activity as determinant of bone conservation in radial diaphysis, **579**
postmenopausal
adjuvant oestrogen treatment and bone mineral density: *concise report*, **302**: *matters arising*, **835**
DHEAS depressed levels, and axial bone density, **211**
no improvement in disease activity with adjuvant oestrogen therapy, **862**
radiological progression, how many patients are required in a treatment trial to test disease modification, **332**
recent onset, bone mineral density, **21**
receptor expression in synovial fluid neutrophils, **354**
renal effects of aspirin and low dose methotrexate: *concise report*, **613**
and rheumatoid factor, prevalence in women, evidence for secular decline, **254**
second line (disease modifying) treatment, which drug for which patient? **423**
self report functional disability scores and use of devices, **497**
serum concentrations of IL-2 receptor, effect of second line drugs: *concise report*, **58**
serum IL-6 levels: *concise report*, **232**
serum osteocalcin and carboxyterminal propeptide of type I procollagen, **338**

and several other idiopathic diseases, reappraisal of evidence that these are slow bacterial infections, **S30**
sex ratios, HLA-DR and testosterone: *correspondence*, **244**
small intestinal bacterial overgrowth, 503: *matters arising*, **895**
stress fractures of pubic rami: *concise report*, **681**
sulphoxidation status: *correspondence*, **168**
susceptibility, analysis of T-cell receptor Vβ segment: *concise report*, **891**
T cell receptor β chain variable region polymorphism, **327**
thyroid dysfunction, controlled prospective study: *concise report*, 454
VCAM-1 and integrins in lymphocyte aggregates, **806**
Rheumatoid factor
isotypes, is measurement clinically useful? *viewpoint*, **161**
and RA, prevalence in women, evidence for secular decline, **254**
Rheumatoid nodules
benign, in woman with chronic lymphocytic leukaemia and borderline lepromatous leprosy: *concise report*, **685**
differential diagnosis and immunohistological findings: *leader*, **625**
palisading cells, comparison with synovial intimal cells, **801**
RSI, see Repetitive strain injury
Rubella associated arthritis, cellular hyperimmunoreactivity to rubella virus synthetic peptides, **590**

Sacral stress fractures, clinical evolution, influence of additional pelvic fractures: *concise report*, **545**
Sacroiliitis, rapidly progressive, in lymphocytic lymphoma: *concise report*, **239**
Sacrum, insufficiency fractures: *correspondence*, **621**
Scleroderma (systemic sclerosis)
antinuclear antibodies in patients and their blood relatives and spouses, **365**
early phenotypic activation of circulating helper memory T cells, and disease activity, **272**
early pulmonary disease, carbon monoxide transfer factor and static lung compliance compared, **725**
fibroblasts in culture, effects of methotrexate on glycosaminoglycan production, **758**
labial capillary microscopy, **564**
and large vessel occlusive disease: *concise report*, **464**: *matters arising*, **837**
and malignancy, epidemiological study, **531**
with severe pulmonary and vascular disease, autoantibodies to centromere and histone, **780**
Self report functional disability scores and use of devices in RA, **497**
Self tolerance, a walk round the edges, **S3**
Shoulder pain, RA, controlled by modified suprascapular nerve block with bupivacaine, **215**
Silica, occupational exposure, multiple clinical and biological autoimmune manifestations, 50 workers, **534**
Sjögren's syndrome
antibodies to retroviral proteins: *correspondence*, **621**
primary
β2 microglobulin measurements in saliva, influence of flow: *concise report*, **461**
hydroxychloroquine treatment, **360**
VCAM-1 and integrins in lymphocyte aggregates, **806**
Skeletal muscle, in SLE, distribution of cell adhesion molecules, **667**
Skin pathergy test, with blunt and sharp needles compared, in Behçet's disease: *concise report*, **823**
Sleep, 'α-δ', elusive, in fibromyalgia and osteoarthritis: *correspondence*, **245**
Slow bacterial infections, reappraisal of evidence that RA and other diseases are, **S30**
Small intestinal bacterial overgrowth in RA, 503: *matters arising*, **895**
Smoking, cigarette, and osteoarthritis risk, women, Chingford study, **93**
Splenic rupture, spontaneous, in Wegener's vasculitis: *correspondence*, **314**
Spondylodiscitis due to *H. aphrophilus*, vacuum sign: *correspondence*, **84**
Steroids, and insulin-like growth factor I, maintain proteoglycan synthesis, **734**
Stress fractures, of pubic rami, in RA: *concise report*, **681**
Stroke, and renal failure, immunosuppressive treatment: *correspondence*, **165**
Sulphasalazine, and hydroxychloroquine, alone and in combination, in RA, **711**
Sulphoxidation status, in RA: *correspondence*, **168**
Superantigens, bacterial and viral, roles in autoimmunity? **S6**
Sympathetic nervous system in chronic joint pain: *matters arising*, **552**
Synovial fluid
cytology, refrigeration preserves: *correspondence*, **384**
identification of metalloproteinase inhibitors, **177**
neutrophils, receptor expression, in RA, **354**
particles, in osteoarthritic knees, and radiographic changes, **97**
and peripheral blood mononuclear cells, responses to bacterial antigens and autologous antigen presenting cells, **127**
T cells
expression of CD69 antigen, RA and other synovitis: *concise report*, **457**
in HTLV-I positive RA: *correspondence*, **166**
Synovial intimal cells, compared with palisading cells of rheumatoid nodules, **801**
Synovial joint, microfibrillar elements, presence of type VI collagen and fibrillin-containing microfibrils, **449**
Synovial lymphocytes, and aetiology of synovitis, **S17**: *matters arising*, **765**
Synovium, arthritic, giant cells, **182**
Systemic connective tissue diseases, 6-thioguanine nucleotide accumulation in erythrocytes during azathioprine treatment, monitoring possibility: *concise report*, **152**
Systemic lupus erythematosus
abnormalities in regulation of variable region genes: *hypothesis*, **378**
and acquired Brown's syndrome: *concise report*, **63**; *correspondence*, **385**: *matters arising*, **835**
assessment, where are we now? *leader*, **169**
cell adhesion molecule distribution in skeletal muscle, **667**
differential heat shock protein overexpression and its clinical relevance, **436**
environmental factors predicting nephritis, **720**
expression in various ethnic Jewish Israeli groups, **268**
predictive value of IgG autoantibodies against C1q for nephritis, **851**
urine neopterin as parameter of disease activity, **429**
Systemic sclerosis *see* **Scleroderma (systemic sclerosis)**

T-cell receptor Vβ segment implicated in susceptibility to RA, analysis, Vβ2 germline polymorphism does not encode susceptibility: *concise report*, **891**
T cells
adhesion to synovial membrane and peripheral lymph node endothelium, role of CS1 adhesion motif of fibronectin, **672**
circulating helper memory, in scleroderma, and disease activity, **272**
Temporomandibular joint, health screening: *correspondence*, **696**
Tenidap, effect on cartilage integrity in vitro, **292**
Testosterone, HLA-DR, and RA sex ratios: *correspondence*, **244**
6-Thioguanine nucleotide accumulation in erythrocytes during azathioprine treatment for systemic connective tissue diseases, monitoring possibility: *concise report*, **152**
Thyroid dysfunction in RA, controlled prospective survey: *concise report*, **454**
Thyroiditis, subacute, and giant cell arteritis, simultaneous onset: *correspondence*, **839**
Tick-borne diseases, relative contributions of transovarial and transstadial transmission to maintenance, **405 *P***
Tick-borne encephalitis
and Lyme borreliosis, seroconversion, Dutch military personnel, **406 *P***
seroepidemiological study, **404 *P***
Tiludronate, oral, five day course, in Paget's disease of bone, **54**
Tophus, rapid development following ipsilateral hemiparesis: *concise report*, **308**
Transforming growth factor-β, in protection from IL-1 induced articular cartilage destruction, **185**
Transforming growth factor β receptor, correlation with TGF-β responses of isolated bovine articular chondrocytes, **812**

Ulceration, gastrointestinal, and RA, risk factors in treatment, **771**
Unclassified arthritis, rational diagnosis and treatment, how clinical data may guide requests for Lyme serology and antibiotic treatment, **206**

Vacuum sign, in spondylodiscitis due to *H. aphrophilus*: *correspondence*, **84**
Vascular cell adhesion molecule 1 and α4 and β1 integrins in lymphocyte aggregates in Sjögren's syndrome and RA, **806**
Vasculitis
cutaneous, and IgA glomerulonephritis, in ankylosing spondylitis: *concise report*, **61**
rheumatoid, impaired endothelial fibrinolytic response, abnormal plasma fibrinolysis, **643**
Venous thrombosis, and antiphospholipid antibodies, patients should receive long term anticoagulant treatment: *concise report*, **689**
Visceral leishmaniasis: *correspondence*, **551**
von Willebrand factor
antigen
and endothelium damage: *correspondence*, **86**
and postural variation: *correspondence*, **82**
exercise, and ischaemia/reperfusion injury: *correspondence*, **245**

Wegener's granulomatosis, occurrence of autoantibodies to human leucocyte elastase, **115**
Wegener's vasculitis, spontaneous splenic rupture: *correspondence*, **314**

Yersinia associated arthritis in SHR rats, effect of host microbial status, **223**
Yttrium-90 silicate, radiosynovectomy, in haemophilic haemarthrosis, long term follow up: *concise report*, **548**